Publication | Open Access
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
58
Citations
52
References
2021
Year
Taken together, our results provide strong preclinical evidence for combining neratinib with CDK4/6, mTOR, and MEK inhibitors for the treatment of HER2<sup>+</sup> cancer.
| Year | Citations | |
|---|---|---|
Page 1
Page 1